Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT03315039 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Liposomal Annamycin

Sponsor

Moleculin Biotech, Inc.